Stem Cell-Based Therapy for Alopecia Areata: Mechanistic Rationale, Clinical Evidence, and Translational Barriers
Alopecia areata (AA) is a chronic inflammatory, non-scarring hair loss disorder with a cumulative lifetime incidence of 2%, spanning localized patches to alopecia totalis (AT) and alopecia universalis (AU). Its pathogenesis centers on collapse of hair follicle immune privilege (IP) and subsequent autoimmune follicular attack, driven by genetic predisposition, immune dysregulation, oxidative stress, microbial factors, and epigenetic modification. Conventional therapies—topical, intralesional, and systemic corticosteroids, cyclosporine, contact immunotherapy (DPCP, SADBE), minoxidil, and Janus kinase (JAK) inhibitors—show efficacy mainly in mild-to-moderate disease, but are constrained by suboptimal response in moderate-to-severe cases, frequent adverse effects, and high relapse rates after cessation. Stem cell-based therapy has emerged as a candidate intervention acting through immunomodulation, oxidative stress mitigation, angiogenesis, and hair follicle cycle activation. Reported modalities include mesenchymal stem cells (MSCs) from bone marrow, adipose tissue, and Wharton's Jelly; cord blood-derived multipotent stem cells; hair follicle stem cells; and induced pluripotent stem cells, with conditioned media as an acellular alternative. Emerging evidence indicates that therapeutic efficacy depends on delivery route and immunological context, with systemic delivery potentially advantageous in moderate-to-severe AA or AU, and a time-dependent interaction between stem cell-based therapies and corticosteroids influencing outcomes. Clinical translation remains limited by absent standardized protocols for cell source, dosage, and delivery route; insufficient long-term safety data on genomic stability and tumorigenic risk; and lack of large-scale randomized controlled trials against established treatments such as JAK inhibitors.